Summary
Between May 1985 and November 1988, 143 adult patients with previously untreated acute nonlymphocytic leukemia were randomized to receive mitoxantrone and cytarabine (MTT+Ara-C) or daunomycin and cytarabine (DNM+Ara-C) in order to compare the efficacy and acute and chronic toxicities. Therapy consisted of 3 days of MTT 12 mg/m2/i.v. or DNM 45 mg/m2/i.v.; both groups received Ara-C 100 mg/m2 daily by continuous infusion (CI) for 7 days. Those who failed to achieve a complete remission after one induction course received a second induction course for 2 and 5 days at the same doses. All the patients who achieved complete remission received two consolidations of 2 days of MTT or DNM and 5 days of Ara-C in CI at the same dose as for induction. Of the 72 patients on MTT+Ara-C, 38 (53%) achieved complete remission, compared with 29 (43%) of 67 treated with DNM+Ara-C. Three and 5 patients had partial remission, 7 and 18 failed to respond, 24 and 15 died in the first 21 days of induction, of those treated with MTT+Ara-C or DNM+Ara-C, respectively (p=0.34). Median duration of complete remission and survival was 185 and 103 days or 165 and 160 days, respectively (p=0.85). More early deaths were observed with MTT+Ara-C due to greater myelosuppression, and a higher incidence of failure with DNM+Ara-C. No significant differences between treatment groups were observed in 21 categories of adverse events. The results demonstrate similar incidence of complete response, length of duration of complete remission, overall survival, and toxicity with MTT+Ara-C and DNM+Ara-C.
Similar content being viewed by others
References
Arlin Z, Case DC, Moore J, Wiernik P, Feldman E, Saleten S, Desai P, Sia L, Cartwright K (1990) Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia. Lederle Cooperative Group. Leukemia 4:177–183
Bennett JM, Catovsky D, Daniel MT et al (1985) Proposed revised criteria for the classification of acute myeloid leukemia. Ann Intern Med 103:626–629
Dillman RO, Davis RB, Green MR, Weiss RB, Gottleib AJ, Caplan S, Koplen S, Pressler H, Schaffer C, McIntyre OR (1987) Comparison of AraC at 200 mg/m2 and 100 mg/m2in induction and maintenance therapy for acute myelocytic leukemia. Proc Annu Meet Am Soc Clin Oncol 6:A629
Gale RP, Cline MG (1977) High remission induction rate in acute myeloid leukaemia. Lancet 1:497
Kaplan E, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457–481
Moore JO, Olsen GA (1984) Mitoxantrone in the treatment of relapsed and refractory acute leukaemia. Semin Oncol 11 [Suppl 1]:41–46
Paciucci PA, Cuttner J, Holland JF (1984) Mitoxantrone in patients with refractory acute leukaemia. Semin Oncol 11 [Suppl 1]: 36–40
Peto R, Pike M, Armitage P et al (1977) Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 35:1–39
Preisler H, Davis RB et al (1987) Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukaemia: a Cancer and Leukaemia Group B study. Blood 69:1441–1449
Preisler HD, Rustum Y, Henderson ES et al (1979) Treatment of acute non-lymphocytic leukaemia: use of anthracycline-cytosine arabinoside induction therapy and comparison of two maintenance regimens. Blood 53:455
Prentice HG, Robbins G, Ma DDF, Ho AD (1984) Mitoxantrone in relapsed and refractory acute leukaemia. Semin Oncol 11 [Suppl 1]: 32–35
Rai KR, Holland JF, Glidewell OJ et al (1981) Treatment of acute myelocytic leukaemia: a study by Cancer and Leukaemia Group B. Blood 58:1203
Shenkenberg TD, Von Hoff DD (1986) Mitoxantrone: a new anticancer drug with significant clinical activity. Ann Intern Med 105:67–81
Wahlin A, Hornsten P, Hedenus M, Malm C (1991) Mitoxantrone and cytarabine versus daunorubicin and cytarabine in previously untreated patients with acute myeloid leukemia. Cancer Chemother Pharmacol 28:480–483
Weiss RB (1989) Mitoxantrone: its development and role in clinical practice. Oncology (Huntingt); 3:135–141
Yates JW, Wallace HJ jr et al (1973) Cytosine arabinoside (SC # 63878) and daunorubicin (NSC # 83142) in acute non-lymphocytic leukaemia. Cancer Chemother Rep 57:485–487
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pavlovsky, S., Llaven, J.G., Martinez, M.A.G. et al. A randomized study of mitoxantrone plus cytarabine versus daunomycin plus cytarabine in the treatment of previously untreated adult patients with acute nonlymphocytic leukemia. Ann Hematol 69, 11–15 (1994). https://doi.org/10.1007/BF01757342
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01757342